Dr. Mingo M.H. YUNG 容銘浩博士
Post-doctoral Fellow Bsc; MPhil (PolyU); PhD (HK) |
|
Laboratory Block, Faculty of Medicine Building, 21 Sassoon Road | |
(852)-3917-9375 |
Publications
2023
- Mo Y, Leung LL, Mak CSL, Wang X, Chan WS, Hui LMN, Tang HWM, Siu MKY, Sharma R, Xu D, Tsui SKW, Ngan HYS, Yung MMH, Chan KKL, Chan DW. Tumor-secreted exosomal miR-141 activates tumor-stroma interactions and controls premetastatic niche formation in ovarian cancer metastasis. Mol Cancer 22, 4 (2023). https://doi.org/10.1186/s12943-022-01703-9
2022
- XUAN Y., WANG H., Yung M.H., Chen F., Chan W.S., Chan Y.S., Tsui S.K.W., Ngan H.Y.S., Chan K.K.L. and Chan D.W., SCD1/FADS2 fatty acid desaturases equipoise lipid metabolic activity and redox-driven ferroptosis in ascites-derived ovarian cancer cells, Theranostics. 2022, 12, 3534-3552.
2021
- WANG X., Yung M.H., Sharma R., Chen F., Poon Y.T., Lam W.Y., Li B., Ngan H.Y.S., Chan K.K.L. and Chan D.W., Epigenetic Silencing of miR-33b Promotes Peritoneal Metastases of Ovarian Cancer by Modulating the TAK1/FASN/CPT1A/NF-κB Axis, Cancers. 2021, 13, 4795. http://dx.doi.org/10.3390/cancers13194795
- Chan D.W., Lam W.Y., Chen F., Yung M.H., Chan Y.S., Chan W.S., He F., Liu S., Chan K.K.L., Li B. and Ngan H.Y.S., Genome-wide DNA methylome analysis identifies methylation signatures associated with survival and drug resistance of ovarian cancers, Clinical Epigenetics. 2021, 13. http://dx.doi.org/10.1186/s13148-021-01130-5
- WANG H., Yung M.H., Ngan H.Y.S., Chan K.K.L. and Chan D.W., The Impact of the Tumor Microenvironment on Macrophage Polarization in Cancer Metastatic Progression, International Journal of Molecular Sciences. 2021, 22, 6560. http://dx.doi.org/10.3390/ijms22126560
- LIANG R., Yung M.H., He F., JIAO P., Chan K.K.L., Ngan H.Y.S. and Chan D.W., The Stress-Inducible BCL2A1 Is Required for Ovarian Cancer Metastatic Progression in the Peritoneal Microenvironment, Cancers. 2021, 13, 4577. http://dx.doi.org/10.3390/cancers13184577
2019
CHEN R., Yung M.H., XUAN Y., ZHAN S., LEUNG L.L., LIANG R., Leung T.H.Y., Yang H.J., Xu D., Sharma R., Chan K.K.L., Ngu S.F., Ngan H.Y.S. and Chan D.W., Targeting of lipid metabolism with a metabolic inhibitor cocktail eradicates peritoneal metastases in ovarian cancer cells, Communications Biology. 2019, 2. http://dx.doi.org/10.1038/s42003-019-0508-1
Li Z., Zhou W., Zhang Y., Sun W., Yung M.H., Sun J., Li J., Chen C.W., Li Z., Meng Y., Chai J., Zhou Y., Liu S., Cheung A.N.Y., Ngan H.Y.S., Chan D.W., Zheng W. and Zhu W., ERK regulates HIF-1α-mediated platinum resistance by directly targeting PHD2 in ovarian cancer, Clinical Cancer Research. 2019, clincanres.4145.2018. http://dx.doi.org/10.1158/1078-0432.CCR-18-4145
Sun J., Cai X., Yung M.H., Zhou W., Li J., Zhang Y., Li Z., Liu S., Cheung A.N.Y., Ngan H.Y.S., Li Y., Dai Z., Kai Y., Tzatsos A., Peng W., Chan D.W. and Zhu W., miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer, Oncogene. 2019, 38, 564-580. http://dx.doi.org/10.1038/s41388-018-0459-x
Sun J, Cai X, YUNG MMH, Zhou W, Li J, Zhang Y, Li Z, Liu SS, Cheung AN, Ngan HYS, Li Y, Dai Z, Kai Y, Tzatsos A, Peng W, Chan DW*, Zhu W*. miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer. Oncogene 2019 Jan;38(4):564-580. (* Co-corresponding author)
2018
CHEN K., Liu X., MAK S.L., Yung M.H., Leung T.H.Y., Xu D., Ngu S.F., Chan K.K.L., Yang H.J., Ngan H.Y.S. and Chan D.W., Methylation-associated silencing of miR-193a-3p promotes ovarian cancer aggressiveness by targeting GRB7 and MAPK/ERK pathways , Theranostics. 2018, 8: 423-436. http://dx.doi.org/10.7150/thno.22377 (Publication No. : 284013)
LEUNG L.L., Yung M.H., Ngan H.Y.S. and Chan D.W., Study of hedgehog signaling in cervical cancer, ESMO Open. BMJ, 2018, 3: A89-A89. http://dx.doi.org/10.1136/esmoopen-2018-EACR25.214 (Publication No. : 295865)
Pan Q., Law C.O.K., Yung M.H., Han K.C., Pon Y.L. and Lau T.C.K., Novel RNA aptamers targeting gastrointestinal cancer biomarkers CEA, CA50 and CA72-4 with superior affinity and specificity , PLoS ONE. PLoS ONE, 2018, 13, e0198980. http://dx.doi.org/10.1371/journal.pone.0198980
Sun J., Cai X., Yung M.H., Zhou W., Li J., Zhang Y., Li Z., Liu S., Cheung A.N.Y., Ngan H.Y.S., Li Y., Dai Z., Kai Y., Tzatsos A., Peng W., Chan D.W. and Zhu W., miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer, Oncogene. Springer Nature Limited, 2018. http://dx.doi.org/10.1038/s41388-018-0459-x (Publication No. : 290017)
Yung M.H., Tang W.M., Cai C.H., Leung T.H.Y., Ngu S.F., Chan K.K.L., Xu D., Yang H.U.I.J.U.A.N., Ngan H.Y.S. and Chan D.W., GRO-α and IL-8 enhance ovarian cancer metastatic potential via the CXCR2-mediated TAK1/NFκB signaling cascade, Theranostics. 2018, 8: 1270-1285. http://dx.doi.org/10.7150/thno.22536 (Publication No. : 284377)
Zhou W., Sun W., Yung M.H., Dai S., Cai Y., Chen C.W., Meng Y., Lee J.B., Braisted J.C., Xu Y., Southall N.T., Shinn P., Huang X., Song Z., Chen X., Kai Y., Cai X., Li Z., Hao Q., Cheung A.N.Y., Ngan H.Y.S., Liu S., Barak S., Hao J., Dai Z., Tzatsos A., Peng W., Pei H., Han Z., Chan D.W., Zheng W. and Zhu W., Autocrine activation of JAK2 by IL-11 promotes platinum drug resistance, Oncogene. 2018. http://dx.doi.org/10.1038/s41388-018-0238-8 (Publication No. : 284933)
2017
Chan D.W., Hui W.W., Wang J.J., Yung M.H., Hui M.N., Qin Y.I.M.I.N.G., LIANG R., Leung T.H.Y., Xu D., Chan K.K.L., Yao K.M., Tsang B.K. and Ngan HYS, DLX1 acts as a crucial target of FOXM1 to promote ovarian cancer aggressiveness by enhancing TGF-β/SMAD4 signaling, Oncogene. 2017 Mar;36(10):1404-1416.
Mak CS, Yung MM, Hui LM, Leung LL, Liang R, Chen K, Liu SS, Qin Y, Leung TH, Lee KF, Chan KK, Ngan HY, Chan DW. MicroRNA-141 enhances anoikis resistance in metastatic progression of ovarian cancer through targeting KLF12/Sp1/survivin axis. Mol Cancer. 2017 Jan 17;16(1):11. doi: 10.1186/s12943-017-0582-2.
Mak CS, Yung MMH, Hui LMN, Leung LL, Liang R, Chen KM, Liu SS, Qin Y, Leung THY, Lee KF, Chan KKL, Ngan HYS and Chan DW* Dysregulation of miR-141/KLF12/Sp1/survivin signaling promotes anoikis resistance in ovarian cancer metastatic progression. Mol Cancer 2017 16(1):1-17.
2016
Chan D.W., Hui W.W., Wang J.J., Yung M.H., Hui M.N., Qin Y.I.M.I.N.G., LIANG R., Leung T.H.Y., Xu D., Chan K.K.L., Yao K.M., Tsang B.K. and Ngan H.Y.S., DLX1 acts as a crucial target of FOXM1 to promote ovarian cancer aggressiveness by enhancing TGF-β/SMAD4 signaling, In: Drs. Douglas Green and Justin Stebbing , Oncogene. UK, Macmillan Publishers Limited, 2016, 36: 1404-1416.
Yung MH, Ngan HYS and Chan DW*. Targeting AMPK signaling in combating ovarian cancers: Opportunities and Challenges. Acta Biochimica et Biophysica Sinica. 2016 48(4):301-17.
Yung MH, Ross FA, Hardie DG, Leung TH, Zhan JB, Ngan HYSand Chan DW*. Bitter melon (Momordica charantia) extract functions as a natural AMPK activator and synergistically enhances cisplatin cytotoxicity in ovarian cancer cells. Integrat Cancer Ther. 2016 15(3):376-89. (The most read paper in 2015/16) * (Corresponding author)